SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Pictured: AbbVie sign on a building/courtesy of Ad
Business
AbbVie CEO Gonzalez to Retire July 1 After More Than a Decade at Helm
President and COO Robert Michael will take over Richard Gonzalez’s CEO duties, AbbVie announced Tuesday. Gonzalez will become executive chairman of the board of directors.
February 21, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Handshake in front of raining money / Ta
Business
10 Multibillion-Dollar M&As That Closed Since July 2023
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
February 21, 2024
 · 
6 min read
 · 
Neil Versel
Pictured: A MRI brain scan background, magnetic us
Drug Development
5 Alzheimer’s Data Readouts to Watch in 2024
With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.
February 2, 2024
 · 
4 min read
 · 
Kate Goodwin
Pictured: AbbVie sign on a building/courtesy of Ad
Business
AbbVie Gets Q4 Beat, Sees 2023 Sales Decline in Oncology and Immunology
While AbbVie beat revenue expectations in the fourth quarter of 2023, the company reported Friday that its overall sales last year declined as it faced biosimilar competition for its blockbuster Humira.
February 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: AbbVie Corporate Office/iStock, vzphotos
AbbVie’s Humira Maintains Market Dominance Amid Biosimilar Launches: Report
Despite offering discounts that reach as high as 85%, Humira biosimilars are finding it difficult to take market share away from the AbbVie blockbuster, according to a new report from Samsung Bioepis.
January 18, 2024
 · 
3 min read
 · 
Tristan Manalac
Pictured: Disco ball with bright rays/iStock
Business
AbbVie-Backed Disco Launches with $20M in Funding, Targets Oncology
Disco Pharmaceuticals is taking to the biotech dance floor with seed funding from major players and pipeline programs in small cell lung cancer and colorectal cancer.
January 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Illustration including a brain, the Eart
Policy
Companies Bend Patent System to Head Off Competition Long-Term: Analysis
Brand pharmas not only leverage ancillary patents but sometimes hide or misrepresent information to the U.S. patent office in order to extend market exclusivity and high prices.
January 8, 2024
 · 
5 min read
 · 
Sunitha Chari
Update: AbbVie headquarters building in California
Business
AbbVie Inks Two CAR-T Deals Worth Up to $1.4B with Umoja, Targets Multiple Cancers
The two agreements announced Thursday will allow AbbVie to leverage Umoja Biopharma’s VivoVec delivery platform, which enables patients’ cells to produce their own cancer-fighting CAR-T cells.
January 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: CVS Health's signage outside its office in Texas
CVS to Remove AbbVie’s Humira from Reimbursement Lists, Cover Biosimilars
The pharmacy benefit management subsidiary of CVS Health is favoring Humira’s biosimilars for its major formularies, with AbbVie’s branded product to be nixed on April 1, 2024.
January 4, 2024
 · 
3 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
BioMidwest
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
April 12, 2024
 · 
14 min read
Business
AbbVie to Host First-Quarter 2024 Earnings Conference Call
April 4, 2024
 · 
1 min read
Deals
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
March 25, 2024
 · 
9 min read
FDA
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
March 22, 2024
 · 
12 min read
BioMidwest
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
March 7, 2024
 · 
1 min read
Business
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
March 6, 2024
 · 
34 min read
Policy
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
March 5, 2024
 · 
10 min read
BioMidwest
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
February 28, 2024
 · 
8 min read
BioMidwest
AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
 · 
1 min read
Business
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 27, 2024
 · 
15 min read
Load More